Sponsored Video
1.
Specialized Pro-resolving Mediators (SPMs) in Real World Clinical Practice
Metagenics Institute is a trusted, peer-to-peer, evidence-based educational resource for nutrition and personalized medicine. At Metagenics Institute, we translate credible research with scientific integrity into innovative and actionable clinical decision-making. Metagenics Institute supports a diverse practitioner base to optimize patient outcomes by shifting existing paradigms in healthcare. Our mission is to transform healthcare by inspiring and educating practitioners, and their patients, about personalized lifestyle medicine.
2023
Abstract
In this webinar, Dr Jennifer Stagg describes her experience seeing patients who have conditions that involve chronic inflammation and the solutions she uses to manage the underlying inflammation and the condition itself. We know that chronic inflammation is caused by obesity, poor lifestyle, and aging and is associated with a variety of conditions that lead to arthritis, cancer, atherosclerosis, neurological diseases, and insulin resistance and type 2 diabetes. The first step in the process to see if SPMs are an appropriate therapy for a particular patient is assessment. Providers can measure clinically relevant biomarkers of inflammation like hsCRP, TNF-alpha, Ferritin, ESR, and Fibrinogen. Patients might also measure their quality of life by taking a brief pain inventory, such as the American Chronic Pain Association Quality of Life Scale. Dr Stagg's findings show reductions in proinflammatory markers, pain scores, and improvements in pain-related quality of life
Sponsored Video
2.
Real World Clinical Experiences with Specialised Pro-resolving Mediators
Metagenics Institute is a trusted, peer-to-peer, evidence-based educational resource for nutrition and personalized medicine. At Metagenics Institute, we translate credible research with scientific integrity into innovative and actionable clinical decision-making. Metagenics Institute supports a diverse practitioner base to optimize patient outcomes by shifting existing paradigms in healthcare. Our mission is to transform healthcare by inspiring and educating practitioners, and their patients, about personalized lifestyle medicine.
2023
Abstract
This presentation by Dr. Cory Rice is entitled “Specialized Pro-resolving Mediators in Real World Clinical Practice.” This is part of our peer-to-peer knowledge sharing series. Incorporating SPMs in clinical practice for patients with chronic disease, particularly those who need nutritional support for lifestyle medicine. Dr. Rice also provides several patient case studies in which he describes how SPMs have provided improved health outcomes to his patients. As we know, many chronic health conditions are associated with underlying inflammation. SPMs activate the resolution pathway of inflammation so that treatments can be focused on the symptoms of the specific disease.
Sponsored Video
3.
The Role of Specialized Pro-Resolving Mediators in the Resolution of Chronic Inflammation
Metagenics Institute is a trusted, peer-to-peer, evidence-based educational resource for nutrition and personalized medicine. At Metagenics Institute, we translate credible research with scientific integrity into innovative and actionable clinical decision-making. Metagenics Institute supports a diverse practitioner base to optimize patient outcomes by shifting existing paradigms in healthcare. Our mission is to transform healthcare by inspiring and educating practitioners, and their patients, about personalized lifestyle medicine.
2023
Abstract
In this webinar Jennifer Stagg, ND presents an overview of the use of SPMs in clinical practice. Her research shows that the use of SPMs bring about an effective resolution response to chronic and acute inflammation. Dr Stagg presents the causes of most inflammation in both young and old and the symptoms that are associated with its disease pathogenesis. Recorded at the AANP Pre-Conference in Salt Lake City, Utah at the 2016 American Association of Naturopathic Physicians Annual Convention & Exhibition.
Sponsored Case Study
4.
Specialized Pro-Resolving Mediators (SPMs) Case Study
Metagenics Institute is a trusted, peer-to-peer, evidence-based educational resource for nutrition and personalized medicine. At Metagenics Institute, we translate credible research with scientific integrity into innovative and actionable clinical decision-making. Metagenics Institute supports a diverse practitioner base to optimize patient outcomes by shifting existing paradigms in healthcare. Our mission is to transform healthcare by inspiring and educating practitioners, and their patients, about personalized lifestyle medicine.
2023
Abstract
This paper is entitled, “Supplementation with Specialized Pro-Resolving Mediators Reduces Inflammatory Biomarkers and Improves Reported Clinical Symptomology in Subjects with Chronic Inflammatory Conditions: Results from a Multi-Center Open-Case Series” Highlights: Inflammation has 2 phases: initiation and resolution. Many chronic health issues are linked to unresolved inflammation Specialized pro-resolving mediators (SPMs) are endogenous molecules essential for resolution of inflammation but may not be produced in required levels in certain condition Multi-center case study assessed effects of a proprietary SPM supplement (LM-O3) on inflammatory biomarkers in 34 men and women (21-75 y/o) with conditions indicating raised inflammatory tone Results showed a 43% reduction in high-sensitivity C-reactive protein (hs-CRP) at 4 weeks with concurrent reduction in prostaglandin E2 (PGE2) At 8 weeks, hs-CRP remained reduced, and PGE2 was reduced to within normal range Functional measurements including reported measures of pain as well as quality of life indicated continued improvement at 4 and 8 weeks Adverse events were minimal and managed without incident.
Sponsored Podcast
5.
New Hope for Fibromyalgia Patients
Metagenics Institute is a trusted, peer-to-peer, evidence-based educational resource for nutrition and personalized medicine. At Metagenics Institute, we translate credible research with scientific integrity into innovative and actionable clinical decision-making. Metagenics Institute supports a diverse practitioner base to optimize patient outcomes by shifting existing paradigms in healthcare.
2023
Abstract
This podcast features Dr Kara Fitzgerald in conversation with Dr. Erik Lundquist, who heads a large, integrative clinic out in Southern California. Erik recently completed a clinical pilot study looking at the use of SPMs (just 2 gelcaps per day) in patients diagnosed with fibromyalgia (Dr. Lundquist reports that the bulk of these patients have underlying mold exposure or Lyme as the primary etiology for FMS).
Sponsored Video
6.
Resolving Inflammation
Metagenics Institute is a trusted, peer-to-peer, evidence-based educational resource for nutrition and personalized medicine. At Metagenics Institute, we translate credible research with scientific integrity into innovative and actionable clinical decision-making. Metagenics Institute supports a diverse practitioner base to optimize patient outcomes by shifting existing paradigms in healthcare. Our mission is to transform healthcare by inspiring and educating practitioners, and their patients, about personalized lifestyle medicine.
2023
Abstract
Ryan Lazarus, DC contrasts conventional vs. Functional Medicine approaches in the treatment of chronic inflammation, one of the most common chemical imbalances patients are facing today. Chronic inflammation exerts deleterious systemic effects in the body and is linked to most chronic diseases, such as neurodegenerative diseases, pain and energy disorders, gut dysfunction, autoimmunity and allergies, cancer, and aging. Dr. Lazarus describes major biochemical and nutritional players involved in the two distinct phases of inflammation—initiation and resolution. He shares clinical scenarios that can impair patients’ ability to resolve inflammation and describes strategic modalities to help resolve inflammation, namely a superfamily of lipid mediators known as specialized pro-resolving mediators (SPMs).
Sponsored Journal Article
7.
Treatment With a Marine Oil Supplement Alters Lipid Mediators and Leukocyte Phenotype in Healthy Patients and Those With Peripheral Artery Disease
Paper authors: Melinda S. Schaller, MD; Mian Chen, MD; Romain A. Colas, PhD; Thomas A. Sorrentino, MD; Ann A. Lazar, PhD, MS; S. Marlene Grenon, MD, CM; Jesmond Dalli, PhD; Michael S. Conte, MD The Journal of the American Heart Association (JAHA): Cardiovascular and Cerebrovascular Disease is an international, peer-reviewed, open access, scientific journal that publishes all types of original research articles, including studies conducted with human subjects and experimental models, as well as applied clinical, epidemiological, and healthcare policy papers related to cardiovascular and cerebrovascular diseases. Our mission is to assist the science, scientist, and society in creating a world of longer, healthier lives. Our vision is to innovate and incorporate promising technologies to communicate freely-available, high-priority, high-quality content, which accelerates scientific progress and advances heart and brain health. We value integrity, excellence and inclusiveness. JAHA is an official journal of the American Heart Association and seeks to be the leading open access scientific journal with a cardiovascular and cerebrovascular disease remit in the world.
2023
Abstract
What Is New? This is the first study to elucidate the omega‐3 and omega‐6 polyunsaturated fatty acid lipid mediator profile in peripheral artery disease. We have shown that a short‐course, oral marine oil supplement can remodel these lipid mediator pathways to induce a less inflammatory and pro‐resolution phenotype. What Are the Clinical Implications? This study provides a foundation for characterizing biochemical and cellular biomarkers of inflammation and resolution in peripheral artery disease to allow for future work correlating upstream nutritional or pharmacologic interventions, immune cell function, and downstream clinical events.
-
8.
The role of gut microbiome in inflammatory skin disorders: A systematic review.
Widhiati, S, Purnomosari, D, Wibawa, T, Soebono, H
Dermatology reports. 2022;14(1):9188
-
-
-
Free full text
Plain language summary
Gut-skin axis refers to the complex cross-talk between gut bacteria and skin. Although the exact mechanism underlying chronic inflammatory skin conditions is unknown, imbalances in the composition of gut microbes are believed to play a role. Twenty-three studies were included in this systematic review to assess whether gut microbial imbalance may contribute to inflammatory skin conditions such as Psoriasis, Acne Vulgaris, Atopic Dermatitis, and Urticaria. According to this systematic review, immune stimulation, inflammation, and disruption of bacterial composition are common mechanisms in all these skin disorders. A western diet and environmental exposures are found to be contributing to the disruption of bacteria and the pathology of these skin disorders. It has been observed that friendly gut bacteria such as Bifidobacterium are reduced in people with inflammatory skin conditions, whereas elevated levels of pathogenic bacteria such as E. coli and Proteobacteria are present in the gut of patients with inflammatory skin conditions. The abundance of anti-inflammatory bacteria such as Akkermansia muciniphila, Faecalibacterium prausnitzii, Clostridium leptum, Lactobacillus, and Bifidobacterium may protect against inflammatory skin conditions. Further robust studies are required to evaluate the pathogenesis behind inflammatory skin conditions as well as the involvement of gut bacteria in the development and progression of the disease. Healthcare professionals can gain a deeper understanding of gut bacteria that contribute to the pathology of inflammatory diseases as well as how clinically using anti-inflammatory bacterial species may improve the condition of individuals suffering from inflammatory skin conditions.
Abstract
The close relationship between the intestine and the skin has been widely stated, seen from gastrointestinal (GI) disorders often accompanied by skin manifestations. Exactly how the gut microbiome is related to skin inflammation and influences the pathophysiology mechanism of skin disorders are still unclear. Many studies have shown a two-way relationship between gut and skin associated with GI health and skin homeostasis and allostasis. This systematic review aimed to explore the associations between the gut microbiome with inflammatory skin disorders, such as acne, psoriasis, atopic dermatitis, and urticaria, and to discover the advanced concept of this relationship. The literature search was limited to any articles published up to December 2020 using PubMed and EBSCOHost. The review followed the PRISMA guidelines for conducting a systematic review. Of the 319 articles screened based on title and abstract, 111 articles underwent full-text screening. Of these, 23 articles met our inclusion criteria, comprising 13 atopic dermatitis (AD), three psoriasis, four acne vulgaris, and four chronic urticaria articles. Acne vulgaris, atopic dermatitis, psoriasis, and chronic urticaria are inflammation skin disorders that were studied recently to ascertain the relationship of these disorders with dysbiosis of the GI microbiome. All acne vulgaris, psoriasis, and chronic urticaria studies stated the association of gut microbiome with skin manifestations. However, the results in atopic dermatitis are still conflicting. Most of the articles agree that Bifidobacterium plays an essential role as anti-inflammation bacteria, and Proteobacteria and Enterobacteria impact inflammation in inflammatory skin disorders.
-
9.
A Hot Water Extract of Curcuma longa L. Improves Fasting Serum Glucose Levels in Participants with Low-Grade Inflammation: Reanalysis of Data from Two Randomized, Double-Blind, Placebo-Controlled Trials.
Uchio, R, Okuda-Hanafusa, C, Saji, R, Kawasaki, K, Muroyama, K, Murosaki, S, Yamamoto, Y, Hirose, Y
Nutrients. 2022;14(18)
-
-
-
Free full text
Plain language summary
Chronic low-grade inflammation plays a significant role in the development of type 2 diabetes. The hot water extract of turmeric (Curcuma longa L.) has been shown to have anti-inflammatory and antioxidant properties, as well as the ability to lower blood glucose levels in animal models. Curcuma longa L. extract may improve systemic glucose levels by reducing insulin resistance and pancreatic β-cell dysfunction. In this study, the results from two randomised, double-blind, placebo-controlled trials were reanalysed to assess the effects of hot water extract of C. longa on serum glucose levels in overweight individuals with low-grade inflammation. When compared to the placebo group, participants in the Curcuma longa L. group with high hs-CRP levels showed significant improvements in serum hs-CRP levels and fasting blood glucose levels. Healthcare professionals can use the results of this study to understand the potential beneficial effects of Curcuma longa L. extract on systemic glucose regulation in overweight individuals with low-grade inflammation. Further robust research is needed to investigate the effect of Curcuma longa L. extract on reducing proinflammatory cytokines and suppressing the activation of the NF-kB signalling pathway.
Abstract
The dietary spice Curcuma longa L. (C. longa), also known as turmeric, has various biological effects. A hot water extract of C. longa was shown to have anti-inflammatory activities in preclinical and clinical studies. Chronic low-grade inflammation is associated with the disruption of glucose homeostasis, but the effect of C. longa extract on glucose metabolism in humans is poorly understood. Therefore, we investigated the effect of C. longa extracts on serum glucose levels in the presence of low-grade inflammation. We reanalyzed our published data from two randomized, double-blind, placebo-controlled trials in overweight participants aged 50 to 69 years and performed a stratified analysis using the inflammatory marker high-sensitivity C-reactive protein (hsCRP). In both studies, participants took a test food with a hot water extract of C. longa (C. longa extract group, n = 45 per study) or without C. longa extract (placebo group, n = 45 per study) daily for 12 weeks, and we measured the levels of serum hsCRP and fasting serum glucose. The mean baseline hsCRP value was used to stratify participants into two subgroups: a low-hsCRP subgroup (baseline mean hsCRP < 0.098 mg/dL) and a high-hsCRP subgroup (baseline mean hsCRP ≥ 0.098 mg/dL). In the low-hsCRP subgroup, we found no significant difference in fasting serum glucose levels between the two groups in either study, but in the high-hsCRP subgroup, the C. longa extract group had significantly lower levels of serum hsCRP (p < 0.05) and fasting serum glucose (p < 0.05) than the placebo group in both studies. In conclusion, a hot water extract of C. longa may help to improve systemic glucose metabolism in people with chronic low-grade inflammation.
-
10.
Anti-inflammatory effects of resveratrol in patients with cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials.
Teimouri, M, Homayouni-Tabrizi, M, Rajabian, A, Amiri, H, Hosseini, H
Complementary therapies in medicine. 2022;70:102863
-
-
-
Free full text
Plain language summary
Cardiovascular diseases (CVDs) include various heart or/and blood vessel disorders, such as cerebrovascular disease, congenital heart disease, and coronary artery disease. It is well shown that prolonged or chronic inflammation plays a key role in the pathogenesis of several disorders, especially CVDs. Resveratrol has recently been considered a choice for preventing and treating inflammatory conditions. The aim of this study was to evaluate the impact of resveratrol on serum/plasma concentration of specific inflammatory markers - tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and c-reactive protein (CRP) - in patients with CVDs. This study is a systematic review and meta-analysis of six randomised controlled studies with a total of 415 participants. Results show that resveratrol significantly decreases CRP and TNF-α concentration; however, it did not significantly affect the serum concentration of IL-6 in patients with CVDs. Authors conclude that there is a potential preventive effect of resveratrol supplementation on inflammatory conditions in CVD patients. However, larger randomised clinical trials are needed to further investigate and explore the effects of resveratrol supplementations.
Abstract
BACKGROUND Chronic inflammation is one of the most important factors involved in the development and progression of cardiovascular disease (CVDs). Accumulating evidence has described the effect of resveratrol, a natural polyphenolic compound, on biomarkers of inflammation among patients with CVDs; however, findings are controversial. Here we performed a systematic review and meta-analysis of randomized controlled trials to evaluate the effect of resveratrol supplements on TNF-α, IL-6, and CRP levels in CVDs patients. METHODS Online research was conducted in the following database: MEDLINE, EMBASE, Cochrane Library, Web of Science databases, and Scopus. This systematic review and meta-analysis were conducted to investigate the effects of resveratrol supplements on inflammatory biomarkers among patients with CVDs. The meta-analysis was performed using Comprehensive Meta-Analysis (CMA) V3 software. RESULTS Six RCTs met the inclusion criteria and were selected for the current meta-analysis. Our results demonstrated that resveratrol significantly decreases serum levels of CRP (MD = -0.63, 95 % CI: -0.1.13, -0.12; p = 0.01), and TNF-α (MD = -0.55, 95 % CI: -1.04, -0.06; p = 0.02), however, resveratrol had not significant effect on serum concentration of IL-6 (MD = -0.12, 95 % CI: -0.52, 0.27; p = 0.53), in patients with CVDs. CONCLUSION Our results suggest that resveratrol can be used as a potential treatment in patients with CVD by reducing inflammatory conditions.